Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-1301 in Renal Insufficiency and Healthy Subjects
NCT07322016Phase 1Completed
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Start
- Jan 2026
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HRS-1301 in hyperlipidemia, sponsored by Shandong Suncadia Medicine Co., Ltd. Primary endpoints: Maximum concentration at 8 days, Area under the concentration-time curve from time zero to the time of the last quantifiable concentration at 8 days and 1 more. Started Jan 2026; status: completed.
02
Drugs
HRS-1301
03
Conditions
hyperlipidemia
Beyond the preview
Go deeper on NCT07322016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07322016.